Holen Sie sich die Stockscreener-App
494.98
0.84%
4.70
Regeneron Pharmaceuticals Inc Aktie (REGN) Neueste Nachrichten
Truist Securities maintains buy rating on Regeneron stock - Investing.com Australia
Regeneron's weight-loss drug helps patients on Wegovy preserve muscle - Reuters
Hansoh licensing deal provides Regeneron with HS-20094, a GLP-1/GIP receptor agonist - The Pharma Letter
Regeneron's Obesity Trial With Novo Nordisk's Wegovy Hits Lean Target - Benzinga
Regeneron delivers reminder of Libtayo potential in non-melanoma skin cancers - The Pharma Letter
Regeneron Pharmaceuticals (REGN): Citigroup Lowers Price Target to $650 | REGN Stock News - GuruFocus
Citigroup Has Lowered Expectations for Regeneron Pharmaceuticals (NASDAQ:REGN) Stock Price - MarketBeat
Regeneron Says Phase 2 Obesity Study Interim Results Show Semaglutide Combination Preserves Lean Mass - marketscreener.com
bernstein socgen lowers regeneron pharma stock price target By Investing.com - Investing.com India
Amid Rough Waters, Regeneron Puts Nearly $2B on the Line For Chinese Obesity Drug - BioSpace
Kymera Therapeutics Says Atopic Dermatitis Potential Matches Sanofi/Regeneron's Blockbuster Dupixent In Early Biomarker Response - Benzinga
Regeneron Pharmaceuticals (NASDAQ:REGN) Given New $600.00 Price Target at BMO Capital Markets - MarketBeat
Hansoh Pharmaceutical Says Units Entered Into A License Agreement With Regeneron Pharmaceuticals - marketscreener.com
TD Cowen maintains buy rating for Regeneron Pharma stock - Investing.com
bernstein socgen lowers regeneron pharma stock price target - Investing.com
Regeneron Pharmaceuticals (REGN): Analyst Maintains Rating but Lowers Price Target | REGN Stock News - GuruFocus
Regeneron (REGN) Reports Promising Obesity Treatment Trial Results - GuruFocus
Regeneron Pharmaceuticals (REGN) Price Target Lowered by Morgan Stanley | REGN Stock News - GuruFocus
Regeneron reports early data in mid-stage trial of obesity treatment - Seeking Alpha
Morgan Stanley Cuts Regeneron Pharmaceuticals (NASDAQ:REGN) Price Target to $755.00 - MarketBeat
Regeneron (REGN) Faces Challenges Amid Mixed COPD Trial Results - GuruFocus
Regeneron (REGN) Faces Lower Price Target After Itepekimab Setba - GuruFocus
REGN Stock Undervalued At $500? - Forbes
BMO Capital maintains outperform rating on Regeneron Pharma stock - Investing.com
Regeneron says its weight-loss drug helped preserve muscle mass in study - whbl.com
BMO Capital cuts Regeneron Pharma stock price target to $600 By Investing.com - Investing.com India
Is It Time To Buy Regeneron Pharmaceuticals Stock? - Trefis
Regeneron PharmaceuticalsInterim Results From Ongoing Phase 2 Courage Trial - marketscreener.com
Woodstock Corp Has $4.51 Million Stock Position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat
Regeneron pens $2B pact for Hansoh's potential obesity rival to Lilly's Zepbound - Fierce Biotech
Regeneron Pharmaceuticals Partners With Hansoh Pharma to Develop GLP-1 Drug - marketscreener.com
Regeneron (REGN) Faces Price Target Cut Amid Mixed Clinical Data - GuruFocus
Regeneron (REGN) Phase 2 Trial Shows Promising Obesity Treatment Results | REGN Stock News - GuruFocus
Regeneron (REGN) Secures Rights for Promising GLP-1/GIP Drug | REGN Stock News - GuruFocus
Hansoh Pharmaceutical Enters Strategic License Agreement with Regeneron - TipRanks
Regeneron takes aim at Zepbound with deal for Hansoh's obesity asset - FirstWord Pharma
Regeneron inks deal for new obesity drug candidate - Investing.com
Regeneron Expands Clinical-Stage Obesity Portfolio with Strategi - GuruFocus
Regeneron Says Libtayo Shows Strong Results in Adjuvant Skin Cancer Trial - marketscreener.com
ASCO25: Regeneron unpacks positive Libtayo data in adjuvant CSCC as Keytruda stumbles - Clinical Trials Arena
Regeneron Expands Clinical-Stage Obesity Portfolio with Strategic In-Licensing of Novel Dual GLP-1/GIP Receptor Agonist - The Manila Times
Regeneron's weight-loss drug helps preserve muscle mass in study - TradingView
Regeneron Takes On Eli Lilly: Acquires Rights to New GLP-1 Obesity Drug in Massive $2B Deal - Stock Titan
Regeneron to buy bankrupt 23andMe, vows ethical use of customer DNA data (May 19) By Reuters - Investing.com
Regeneron to buy bankrupt 23andMe, vows ethical use of customer DNA data (May 19) - marketscreener.com
Regeneron Agrees to Purchase Most Assets of 23andMe for $256 million - Dark Daily
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Shares Bought by Czech National Bank - MarketBeat
Morgan Stanley Adjusts PT on Regeneron Pharmaceuticals to $755 From $958, Maintains Overweight Rating - marketscreener.com
Why Regeneron Pharmaceuticals, Inc. (REGN) Crashed Last Week - MSN
Regeneron Pharmaceuticals, Inc. (REGN) Shares Plunge Despite Positive Phase 3 Itepekimab Results - MSN
Centre Asset Management LLC Makes New $7.74 Million Investment in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat
FDA Action Alert: Merck, Moderna, Gilead, Regeneron/Sanofi and More - BioSpace
Regeneron (REGN) Target Price Cut Amid Mixed Phase 3 Results | REGN Stock News - GuruFocus
23andMe Faces Auction Restart As Bid Conflicts Arise - Finimize
Regeneron (REGN) Highlights Promising Phase 3 Trial Results for Libtayo | REGN Stock News - GuruFocus
23andMe to reopen bankruptcy court auction after Anne Wojcicki group's offer - The Business Journals
Temu Parent PDD, Regeneron Pharmaceutical And Burlington Stores Are Among Top 11 Large-Cap Losers Last Week (May 26-May 30): Are The Others In Your Portfolio? - Benzinga
The week in pharma: action, reaction and insight – week to May 30 - The Pharma Letter
GAMMA Investing LLC Has $517.29 Million Stock Position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat
Rep. Byron Donalds Sells Off Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat
Toronto Dominion Bank Raises Stock Position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat
PKO Investment Management Joint Stock Co Invests $7.69 Million in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat
Universal Beteiligungs und Servicegesellschaft mbH Purchases Shares of 178,590 Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat
Pharmaceutical Stocks To Watch NowMay 30th - MarketBeat
Regeneron Pharmaceuticals (NasdaqGS:REGN) Reports 27% Reduction In COPD Exacerbations In Phase 3 Trial - simplywall.st
1.21%
2.22%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):